AllianceBernstein
TSHA icon

AllianceBernstein’s Taysha Gene Therapies TSHA Stock Holding History

AllianceBernstein’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
247,680
+58,440
+31% +$346K ﹤0.01% 2342
2026
Q1 		$1.04M Buy
189,240
+9,600
+5% +$44.6K ﹤0.01% 2328
2025
Q4 		$988K Hold
179,640
– – ﹤0.01% 2345
2025
Q3 		$587K Buy
179,640
+20
+0% +$57 ﹤0.01% 2593
2025
Q2 		$415K Buy
179,620
+71,370
+66% +$155K ﹤0.01% 2749
2025
Q1 		$150K Hold
108,250
– – ﹤0.01% 2995
2024
Q4 		$187K Hold
108,250
– – ﹤0.01% 3033
2024
Q3 		$218K Buy
108,250
+12,650
+13% +$27.8K ﹤0.01% 3015
2024
Q2 		$214K Buy
+95,600
New +$278K ﹤0.01% 3011

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein's TSHA Position: Q2 2026 in Review

AllianceBernstein increased its Taysha Gene Therapies (TSHA) stake by 31% in Q2 2026, buying an estimated $346K and bringing the position to 247,680 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2342.

AllianceBernstein first reported a position in TSHA in Q2 2024 and has held it in 9 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • AllianceBernstein held 247,680 shares of Taysha Gene Therapies worth $1.11M as of Q2 2026.
  • AllianceBernstein bought 58,440 Taysha Gene Therapies shares in Q2 2026, an estimated $346K.
  • Taysha Gene Therapies made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2342 holding.
  • AllianceBernstein first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 9 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.